Coenzyme Q10 in Huntingtons Disease (HD).

Trial Profile

Coenzyme Q10 in Huntingtons Disease (HD).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms 2CARE
  • Most Recent Events

    • 02 Dec 2016 Primary endpoint (Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived) has not been met, according to results of an interim analysis for futility, published in the Neurology journal.
    • 02 Dec 2016 Results of an interim analysis for futility, published in the Neurology journal.
    • 29 Feb 2016 Status changed from active, no longer recruiting to discontinued as the futility analysis failed to show likelihood of benefit of CoQ 2400 mg/day, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top